Specialised Diagnostic testing for early invasive breast cancer patients
In plain English
The notice doesn't say
The notice as published
Provision of the Oncotype DX Breast Recurrence Score test. Oncotype DX genomic testing for breast cancer.<br/><br/>This notice is confirmation of an award having been made based on a framework agreement and without competition.<br/><br/>The lifetime value of the contract is expected to be £326,700.00 call off order.<br/><br/>The contract dates are 14 March 2026 to 13 March 2027. <br/><br/>This is an existing service with an existing provider.